A01N 43/16 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un ou plusieurs atomes d'oxygène ou de soufre comme uniques hétéro-atomes du cycle avec un hétéro-atome des cycles à six chaînons avec l'oxygène comme hétéro-atome du cycle
A01P 21/00 - Régulateurs de croissance des végétaux
The present invention is in the technical field of synthetic biology, metabolic engineering and cell cultivation. The present invention relates to methods for the production of a sialylated compound comprising Gal-β1,3-[Neu5Ac-α2,6]-HexNAc-R as well as the purification of said sialylated compound. The present invention also provides a cell for production of said sialylated compound and the use of said cell in a cultivation or incubation. The present invention also relates to methods and a cell for the production of sialyltransferases having alpha-2,6-sialyltransferase activity on the N-acetylhexosamine (HexNAc) residue of Gal-β1,3-HexNAc-R and/or Neu5Ac-α2,3-Gal-β1,3-HexNAc-R, wherein said sialyltransferases are involved in the production of a sialylated compound comprising Gal-β1,3-[Neu5Ac-α2,6]-HexNAc-R.
C12N 1/00 - Micro-organismes, p. ex. protozoairesCompositions les contenantProcédés de culture ou de conservation de micro-organismes, ou de compositions les contenantProcédés de préparation ou d'isolement d'une composition contenant un micro-organismeLeurs milieux de culture
The present invention is in the technical field of synthetic biology, metabolic engineering and cell cultivation. The present invention relates to methods for the production of a sialylated oligosaccharide comprising Gal-β1,3-[Neu5Ac-α2,6]-HexNAc-R as well as the purification of said sialylated oligosaccharide. The present invention also provides a cell for production of said sialylated oligosaccharide and the use of said cell in a cultivation or incubation. The present invention also relates to methods and a cell for the production of sialyltransferases having alpha-2,6-sialyltransferase activity on the N-acetylhexosamine (HexNAc) residue of Gal-β1,3-HexNAc-R and/or Neu5Ac-α2,3-Gal-β1,3-HexNAc-R, wherein said sialyltransferases are involved in the production of a sialylated oligosaccharide comprising Gal-β1,3-[Neu5Ac-α2,6]-HexNAc-R.
C12N 1/00 - Micro-organismes, p. ex. protozoairesCompositions les contenantProcédés de culture ou de conservation de micro-organismes, ou de compositions les contenantProcédés de préparation ou d'isolement d'une composition contenant un micro-organismeLeurs milieux de culture
The present invention is in the technical field of synthetic biology, metabolic engineering and cell cultivation. The present invention relates to newly identified sialyltransferases having alpha-2, 3-sialyltransferase activity on the galactose residue of lactose. The invention also describes methods for the production of a 3′sialylated oligosaccharide using any one of the newly identified sialyltransferases as well as the purification of the 3′sialylated oligosaccharide. The present invention also provides a cell for production of the 3′sialylated oligosaccharide and the use of the cell in a cultivation or incubation.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
5.
METABOLICALLY ENGINEERED ORGANISMS FOR THE PRODUCTION OF ADDED VALUE BIO-PRODUCTS
The present invention relates to genetically engineered organisms, especially microorganisms such as bacteria and yeasts, for the production of added value bio-products such as specialty saccharide, activated saccharide, nucleoside, glycoside, glycolipid or glycoprotein. More specifically, the present invention relates to host cells that are metabolically engineered so that they can produce said valuable specialty products in large quantities and at a high rate by bypassing classical technical problems that occur in biocatalytical or fermentative production processes.
C12N 9/26 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2) agissant sur les liaisons alpha-glucosidiques-1, 4, p. ex. hyaluronidase, invertase, amylase
C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
C12N 15/81 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour champignons pour levures
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
This disclosure lies in the technical field of drying an oligosaccharide. This disclosure discloses a method for drying an oligosaccharide or mixture of at least two oligosaccharides by using agitated thin film drying (ATFD), wherein the oligosaccharide or each oligosaccharide of the mixture has a degree of polymerization that is lower than 16.
Newly identified alpha-2,6-sialyltransferases are disclosed herein. The disclosure also provides for production of sialylated di- and/or oligosaccharides and relates to the use of the sialyltransferases in such methods and cells. The disclosure is also in the technical field of synthetic biology and metabolic engineering. More particularly, the disclosure is in the technical field of metabolically engineered cells and use of the cells in a cultivation or incubation. The disclosure describes a metabolically engineered cell and a method by cultivation or incubation with the cell for production of 6′sialylated disaccharide and/or 6′sialylated oligosaccharide. Furthermore, the disclosure provides for purification of the 6′sialylated disaccharide and/or 6′sialylated oligosaccharide from the cultivation or incubation.
A simple method for animal free lactose synthesis The present invention relates to methods to produce lactose, more specifically without the need for isolation from mammalian milk. Furthermore, the present invention provides for methods to purify the produced lactose.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
C12P 19/24 - Préparation de composés contenant des radicaux saccharide préparés par action d'une isomérase, p. ex. fructose
9.
METHOD TO IMPROVE A PLANT'S GROWTH, DEVELOPMENT AND RESISTANCE TO (A)BIOTIC STRESS
A01N 43/16 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un ou plusieurs atomes d'oxygène ou de soufre comme uniques hétéro-atomes du cycle avec un hétéro-atome des cycles à six chaînons avec l'oxygène comme hétéro-atome du cycle
A01P 21/00 - Régulateurs de croissance des végétaux
C05F 1/00 - Engrais fabriqués à partir de cadavres d'animaux ou de parties de ceux-ci
A01N 25/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, caractérisés par leurs formes, ingrédients inactifs ou modes d'applicationSubstances réduisant les effets nocifs des ingrédients actifs vis-à-vis d'organismes autres que les animaux nuisibles
10.
METHOD TO IMPROVE A PLANT'S GROWTH, DEVELOPMENT AND RESISTANCE TO (A)BIOTIC STRESS
A01N 43/16 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un ou plusieurs atomes d'oxygène ou de soufre comme uniques hétéro-atomes du cycle avec un hétéro-atome des cycles à six chaînons avec l'oxygène comme hétéro-atome du cycle
The present invention relates to methods to produce crystalline lactose, more specifically lactose obtained from a biotechnological production process.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
C12P 19/24 - Préparation de composés contenant des radicaux saccharide préparés par action d'une isomérase, p. ex. fructose
C13B 20/14 - Purification des jus sucrés utilisant des matériaux échangeurs d'ions
C13B 20/16 - Purification des jus sucrés par des moyens physiques, p. ex. par osmose ou par filtration
C13B 30/00 - CristallisationAppareils de cristallisationSéparation des cristaux à partir des liqueurs mères
A23L 33/00 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement
A61Q 19/00 - Préparations pour les soins de la peau
The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of cultivation of genetically engineered cells. The present invention describes (i) a method for the production of a lacto-N-triose (LN3)-containing oligosaccharide or an oligosaccharide mixture comprising a LN3-containing oligosaccharide by cultivating a genetically modified cell comprising a transporter protein; as well as (ii) the genetically engineered cell used in the method.
C07K 14/195 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
13.
METHOD TO IMPROVE A PLANT'S GROWTH, DEVELOPMENT AND RESISTANCE TO (A)BIOTIC STRESS
A01N 43/16 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un ou plusieurs atomes d'oxygène ou de soufre comme uniques hétéro-atomes du cycle avec un hétéro-atome des cycles à six chaînons avec l'oxygène comme hétéro-atome du cycle
A01N 43/16 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un ou plusieurs atomes d'oxygène ou de soufre comme uniques hétéro-atomes du cycle avec un hétéro-atome des cycles à six chaînons avec l'oxygène comme hétéro-atome du cycle
The present invention is in the technical field of synthetic biology, metabolic engineering and cell cultivation. The present invention relates to newly identified sialyltransferases having alpha-2,3- sialyltransferase activity on an acceptor which is a saccharide comprising at least one N-acetylglucosamine monosaccharide and a galactose monosaccharide. The invention also describes methods for the production of a 3'sialylated oligosaccharide using any one of said newly identified sialyltransferases as well as the purification of said 3'sialylated oligosaccharide. The present invention also provides a cell for production of said 3'sialylated oligosaccharide and the use of said cell in a cultivation or incubation.
C12P 19/26 - Préparation d'hydrates de carbone contenant de l'azote
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
This disclosure is in the technical field of synthetic biology, metabolic engineering and cell cultivation. The disclosure describes methods for the production of a fucosylated compound using a fucosyltransferase as well as the purification of the fucosylated compound, the fucosyltransferase having alpha-1,3-fucosyltransferase activity on the N-acetylglucosamine (GlcNAc) and/or the glucose (Glc) residue of Gal-β1,m-GlcNAc-β1,n-Gal-β1,4-Glc of a saccharide substrate comprising Gal-β1,m-GlcNAc-β1,n-Gal-β1,4-Glc wherein the m is 3 or 4 and the n is 3 or 6. The disclosure also provides a cell for production of a fucosylated compound. Next, the disclosure describes methods for the production of 3-fucosyllactose (3-FL) using a fucosyltransferase having alpha-1,3-fucosyltransferase activity on the Glc residue of lactose, as well as the purification of the 3-FL. The disclosure also provides a cell for production of 3-FL.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
The present invention is in the technical field of synthetic biology, metabolic engineering and cell cultivation. The present invention describes methods for the production of a fucosylated compound comprising Gal-β1,3-[Fuc-α1,4]-GlcNAc using a fucosyltransferase as well as the purification of said fucosylated compound, said fucosyltransferase having alpha-1,4-fucosyltransferase activity on the N-acetylglucosamine (GlcNAc) residue of Gal-β1,3-GlcNAc (lacto-N-biose, LNB) and/or Gal-β1,3-GlcNAc of a saccharide substrate comprising Gal-β1,3-GlcNAc. The present invention also provides a cell for production of a fucosylated compound comprising Gal-β1,3-[Fuc-α1,4]-GlcNAc.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
C07H 15/12 - Radicaux acycliques non substitués par des structures cycliques liés à un atome d'azote d'un radical saccharide
The present invention relates to a method to reduce the feed conversion ratio (FCR) of a farmed animal, wherein said method comprises the step of administering (i) a fucosylated mammalian milk oligosaccharide, (ii) a sialylated mammalian milk oligosaccharide, or (iii) a fucosylated mammalian milk oligosaccharide and a sialylated mammalian milk oligosaccharide. It further relates to the use of (i) a fucosylated mammalian milk oligosaccharide, (ii) a sialylated mammalian milk oligosaccharide, or (iii) a fucosylated mammalian milk oligosaccharide and a sialylated mammalian milk oligosaccharide to reduce the FCR of a farmed animal. It also relates to a method to increase the body weight of a farmed animal, wherein said method comprises the step of administering a fucosylated mammalian milk oligosaccharide and a sialylated mammalian milk oligosaccharide.
The present invention relates to a fucosylated mammalian milk oligosaccharide (MMO) for use in a method for preventing and/or treating shipping fever in an animal, more specifically in a farmed animal or a domesticated animal. More specifically, the invention relates to a fucosylated mammalian milk oligosaccharide (MMO) for use in a method for preventing and/or treating shipping fever pneumonia and/or shipping fever diarrhea in an animal, more specifically in a farmed animal or a domesticated animal.
The disclosure is in the technical field of synthetic biology and metabolic engineering. More particularly, the disclosure is in the technical field of metabolically engineered cells and use of the cells in a cultivation or fermentation. The disclosure describes a cell and a method for production of a di- and/or oligosaccharide. The cell comprises a pathway for production of the di- and/or oligosaccharide and is genetically modified for expression and/or overexpression of at least one set of multiple coding DNA sequences wherein the multiple coding DNA sequences within one set differ in nucleotide sequence and each encode a polypeptide, wherein the polypeptides have the same function and/or activity of interest. Furthermore, the disclosure provides for purification of the di- and/or oligosaccharide from the cultivation.
The present invention relates to a fucosylated mammalian milk oligosaccharide (MMO) for use in a method for preventing and/or treating pneumonia in a farmed animal or a domesticated animal.
The present invention is in the technical field of synthetic biology, metabolic engineering and cell cultivation. The invention provides a cell for production of a negatively charged, preferably sialylated, oligosaccharide wherein said cell is genetically engineered to possess or express, preferably to over-express a hydrolyzing UDP-N-acetyl-D-glucosamine-2-epimerase. The invention further provides use of said cell in a cultivation or incubation. The invention also describes methods for the production of a negatively charged, preferably sialylated, oligosaccharide using said cell as well as the purification of said negatively charged, preferably sialylated, oligosaccharide.
C12N 9/24 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2)
C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
C12P 19/00 - Préparation de composés contenant des radicaux saccharide
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of metabolically engineered cells and use of said cells in a cultivation, preferably a fermentation. The present invention describes a cell and a method for production of a compound. The cell expresses an alpha-1,2-fucosyltransferase that has galactoside alpha-1,2-fucosyltransferase activity on the galactose residue of Gal-b1,3-GlcNAc (LNB, lacto-N-biose). Furthermore, the present invention provides for purification of said compound from the cultivation.
The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of metabolically engineered cells and use of said cells in a cultivation, preferably fermentation. The present invention describes a metabolically engineered cell and a method by cultivation, preferably fermentation, with said cell for production of a bioproduct. More specifically, the present invention describes a metabolically engineered cell and a method by cultivation, preferably fermentation, with said cell for production of an N-acetylneuraminic acid (Neu(n)Ac)-containing compound, wherein (n) is 4, 5, 7, 8 or 9 or a combination thereof. The metabolically engineered cell comprises a pathway for production of said Neu(n)Ac-containing compound and is modified in the expression or activity of at least one NeuNAc synthase according to the present invention. Furthermore, the present invention provides for purification of said Neu(n)Ac-containing compound from the cultivation.
C12N 9/24 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2)
C12P 17/06 - Préparation de composés hétérocycliques comportant O, N, S, Se ou Te comme uniques hétéro-atomes du cycle l'oxygène comme unique hétéro-atome du cycle contenant un hétérocycle à six chaînons, p. ex. fluorescéine
This disclosure is in the technical field of synthetic biology and metabolic engineering. More particularly, this disclosure is in the technical field of fermentation of metabolically engineered yeast or fungal cells. This disclosure describes a method for the extracellular production of a di- or oligosaccharide that is derived from UDP-GlcNAc by a yeast or fungal cell as well as the separation of the di- or oligosaccharide from the cultivation. Furthermore, this disclosure provides a metabolically engineered yeast or fungal cell for extracellular production of a di- or oligosaccharide that is derived from UDP-GlcNAc and that is synthesized in the cytosol.
The present invention is in the technical field of synthetic biology, metabolic engineering and cell cultivation. The invention provides a cell for production of a saccharide wherein synthesis of lactobionic acid in said cell is rendered less functional or is knocked out. The invention further provides use of said cell in a cultivation or incubation. The invention also describes methods for the production of a saccharide using said cell as well as the purification of said saccharide.
C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
27.
PRODUCTION OF A SACCHARIDE, LACTOBIONIC ACID AND/OR GLYCOSYLATED FORMS OF LACTOBIONIC ACID
The present invention is in the technical field of synthetic biology, metabolic engineering and cell cultivation. The invention provides a cell for production of a saccharide with enhanced synthesis of lactobionic acid (LBA) and use of said cell in a cultivation or incubation. The invention also describes methods for the production of a saccharide or of a mixture of a saccharide and LBA using said cell as well as the purification of said saccharide or said mixture of said saccharide and LBA. The invention also provides a cell for production of a glycosylated form of LBA and use of said cell in a cultivation or incubation. Furthermore, the invention describes methods for the production of a glycosylated form of LBA using said cell, as well as for the production of a mixture comprising i) a glycosylated form of LBA and a saccharide or ii) a glycosylated form of LBA, a saccharide and LBA. The invention also describes purification of said glycosylated form of LBA or of a mixture comprising i) a glycosylated form of LBA and a saccharide or ii) a glycosylated form of LBA, a saccharide and LBA.
C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
The present invention is in the technical field of synthetic biology, metabolic engineering and cell cultivation. The invention provides a cell for production of a disaccharide and/or an oligosaccharide like a milk oligosaccharide wherein synthesis of UDP-N-acetylglucosamine in said cell is rendered less functional. The invention further provides use of said cell in a cultivation or incubation. The invention also describes methods for the production of a disaccharide and/or an oligosaccharide like a milk oligosaccharide using said cell as well as the purification of said disaccharide and/or oligosaccharide like a milk oligosaccharide.
C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
The present invention relates to methods for the purification of an oligosaccharide or oligosaccharide mixture from a fermentation broth, a product of such processes, and the use of a product of such processes.
The present invention relates to methods for the purification of a saccharide from a fermentation broth, a product of such processes, and the use of a product of such processes.
The present invention relates to processes for the purification of an oligosaccharide or oligosaccharide mixture from a solution, a product of such processes, and the use of a product of such processes.
B01D 15/18 - Adsorption sélective, p. ex. chromatographie caractérisée par des caractéristiques de structure ou de fonctionnement relatives aux différents types d'écoulement
B01D 15/36 - Adsorption sélective, p. ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction ionique, p. ex. échange d'ions, paire d'ions, suppression d'ions ou exclusion d'ions
C12P 19/00 - Préparation de composés contenant des radicaux saccharide
B01J 39/00 - Échange de cationsUtilisation d'une substance comme échangeur de cationsTraitement d'une substance en vue d'améliorer ses propriétés d'échange de cations
C07H 1/00 - Procédés de préparation des dérivés du sucre
C12P 1/00 - Préparation de composés ou de compositions, non prévue dans les groupes , utilisant des micro-organismes ou des enzymesProcédés généraux de préparation de composés ou de compositions utilisant des micro-organismes ou des enzymes
32.
PRODUCTION OF A SIALYLATED OLIGOSACCHARIDE MIXTURE BY A CELL
This disclosure is in the technical field of synthetic biology and metabolic engineering. More particularly, this disclosure is in the technical field of cultivation or fermentation of metabolically engineered cells. This disclosure describes a cell metabolically engineered for production of a mixture of at least three different sialylated oligosaccharides. Furthermore, this disclosure provides a method for the production of a mixture of at least three different sialylated oligosaccharides by a cell as well as the purification of at least one of the sialylated oligosaccharides from the cultivation.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
33.
CELLULAR PRODUCTION OF SIALYLATED DI- AND/OR OLIGOSACCHARIDES
The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of metabolically engineered cells of microorganisms and the use of said cells in a fermentation. The present invention describes a metabolically engineered cell of a microorganism and a method by fermentation with said cell for production of a sialylated di- and/or oligosaccharide. The metabolically engineered cell comprises a pathway for production of said sialylated di- and/or oligosaccharide, synthesizes sialic acid, expresses at least one sialyltransferase, preferably is modified in the expression or activity of at least one sialyltransferase, is modified to have a fully or partially knocked out or rendered less functional sialic acid catabolic pathway and is modified for overexpression of an endogenous sialic acid transporter and/or expression, preferably overexpression, of an exogenous, homologous and/or heterologous sialic acid transporter. Furthermore, the present invention provides for purification of said sialylated di- and/or oligosaccharide from the cultivation, preferably fermentation.
The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of metabolically engineered cells and use of said cell in a cultivation, preferably a fermentation. The present invention describes a cell for the production of a compound. The cell comprises a pathway for the production of the compound, which can be a disaccharide, oligosaccharide and/or a Neu(n)Ac-containing bioproduct, wherein (n) is 4, 5, 7, 8 or 9 or a combination thereof. The cell is metabolically engineered for enhanced synthesis of acetyl-Coenzyme A. The invention also resides in a method of producing such compound by cultivation, preferably a fermentation, with such a cell.
C12N 9/00 - Enzymes, p. ex. ligases (6.)ProenzymesCompositions les contenantProcédés pour préparer, activer, inhiber, séparer ou purifier des enzymes
C12N 9/04 - Oxydoréductases (1.), p. ex. luciférase agissant sur des groupes CHOH comme donneurs, p. ex. oxydase de glucose, déshydrogénase lactique (1.1)
The present invention relates to a sialylated saccharide for use in a method for preventing and/or treating an inflammatory disease and/or autoimmune disease in a subject, more specifically for preventing and/or treating a disease that causes joint inflammation, even more specifically for preventing and/or treating arthritis. The invention further relates to a method for maintaining and/or improving mobility in a healthy subject. Finally, the invention relates to a method for maintaining and/or improving joint function and/or muscle strength in a healthy subject.
A61K 31/702 - Oligosaccharides, c.-à-d. ayant trois à cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
36.
SIALYLATED SACCHARIDE FOR USE IN THE PREVENTION OR TREATMENT OF AN INFLAMMATORY DISEASE AND/OR AUTOIMMUNE DISEASE
The present invention relates to a sialylated saccharide for use in a method for preventing and/or treating an inflammatory disease and/or autoimmune disease in a subject, more specifically for preventing and/or treating a disease that causes joint inflammation, even more specifically for preventing and/or treating arthritis. The invention further relates to a method for maintaining and/or improving mobility in a healthy subject. Finally, the invention relates to a method for maintaining and/or improving joint function and/or muscle strength in a healthy subject.
A61K 31/702 - Oligosaccharides, c.-à-d. ayant trois à cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
NN-triose (LN3, GlcNAc-beta1,3-Gal-beta1,4-Glc). The invention also provides the use of said cells in a cultivation or incubation. The invention also describes methods for the production of one or more bioproduct(s) using any one of said saccharide importers as well as the purification of said bioproduct(s). The invention furthermore relates to saccharide importers having uptake activity for LN3 and the use of any one of said saccharide importers for the production of one or more bioproduct(s).
Described is a method of producing an oligosaccharide comprising a lacto-N-triose (LN3; GlcNAc-beta1,3-Gal-beta1,4-Glc) as a core trisaccharide by cultivation with a genetically modified cell, as well as the genetically modified cell used in the method. The genetically modified cell comprises at least one nucleic acid sequence coding for a galactoside beta-1,3-N-acetylglucosaminyltransferase and a glycosyltransferase involved in the synthesis of an oligosaccharide comprising LN3 as a core trisaccharide and at least one nucleic acid sequence expressing a membrane protein. Furthermore, the present invention provides for a purification of the oligosaccharide comprising LN3 as a core trisaccharide from the cultivation.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
The present invention lies in the technical field of encapsulating an active agent. The present application discloses an encapsulate comprising (i) an active agent which comprises a milk saccharide or a mixture of at least two different milk saccharides, wherein said milk saccharide and said milk saccharides are obtained from an in vitro and/or ex vivo culture of cells, and (ii) a first carrier material which either forms a shell around the active agent as to form an encapsulate of the core-shell type or forms a matrix wherein the active agent is distributed as to form an encapsulate of the matrix type.
A23K 50/80 - Produits alimentaires spécialement conçus pour des animaux spécifiques pour les animaux aquatiques, p. ex. pour les poissons, les crustacés ou les mollusques
A23L 29/30 - Aliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des sirops d'hydrate de carboneAliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des sucresAliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des alcools de sucre, p. ex. du xylitolAliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des hydrolysats d'amidon, p. ex. de la dextrine
A23P 10/35 - Mise en capsules de particules, p. ex. additifs alimentaires avec des huiles, des lipides, des monoglycérides ou des diglycérides
A61K 31/702 - Oligosaccharides, c.-à-d. ayant trois à cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques
A23K 40/30 - Mise en forme ou traitement des produits alimentaires pour animaux par encapsulationMise en forme ou traitement des produits alimentaires pour animaux par revêtement
40.
BAKED NUTRITIONAL COMPOSITIONS COMPRISING HUMAN MILK OLIGOSACCHARIDES
The present invention relates to a heated, more specifically baked, nutritional composition comprising a milk saccharide or a mixture of at least two different milk saccharides.
A23K 10/16 - Ajout de micro-organismes ou de leurs produits d’extraction, p. ex. de protéines provenant d’organismes unicellulaires, à des compositions de produits alimentaires
A23K 10/20 - Produits alimentaires pour animaux à base de matières d’origine animale
A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine végétale, p. ex. de racines, de graines ou de foinProduits alimentaires pour animaux à base de matières d’origine fongique, p. ex. de champignons
A23K 20/153 - Acides nucléiquesLeurs hydrolysats ou dérivés
This disclosure is in the technical field of synthetic biology and metabolic engineering. More particularly, this disclosure is in the technical field of cultivation of metabolically engineered cells. This disclosure describes a method for the production of a glycosylated product derived from UDP-GlcNAc and comprising a di- or oligosaccharide that is composed of at least two different monosaccharide subunits by a cell as well as the separation of the glycosylated product from the cultivation. Furthermore, this disclosure provides a metabolically engineered cell for production of a glycosylated product derived from UDP-GlcNAc and comprising a di- or oligosaccharide that is composed of at least two different monosaccharide subunits. This disclosure also provides a cell excreting a di- or oligosaccharide out of the cell.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
The present invention relates to processes for the purification of an oligosaccharide from a solution, a product of such processes, and the use of a product of such processes.
B01D 15/12 - Adsorption sélective, p. ex. chromatographie caractérisée par des caractéristiques de structure ou de fonctionnement relatives à la préparation de l'alimentation
B01D 15/36 - Adsorption sélective, p. ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction ionique, p. ex. échange d'ions, paire d'ions, suppression d'ions ou exclusion d'ions
C12P 19/00 - Préparation de composés contenant des radicaux saccharide
B01J 41/00 - Échange d'anionsUtilisation d'une substance comme échangeur d'anionsTraitement d'une substance en vue d'améliorer ses propriétés d'échange d'anions
C12P 1/00 - Préparation de composés ou de compositions, non prévue dans les groupes , utilisant des micro-organismes ou des enzymesProcédés généraux de préparation de composés ou de compositions utilisant des micro-organismes ou des enzymes
Described is a method of producing bioproducts by fermentation with a genetically modified cell, as well as to the genetically modified cell used in the method. The cell is genetically modified to produce a bioproduct and is further genetically modified by reducing the expression of at least one endogenous membrane protein encoding gene and/or mutating the expression of the endogenous membrane protein.
This disclosure is in the technical field of cell cultivation or fermentation for the production of oligosaccharides. The present application discloses a process for purification of an oligosaccharide solution produced by microbial fermentation.
C12P 19/04 - Polysaccharides, c.-à-d. composés contenant plus de cinq radicaux saccharide reliés entre eux par des liaisons glucosidiques
B01D 15/36 - Adsorption sélective, p. ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction ionique, p. ex. échange d'ions, paire d'ions, suppression d'ions ou exclusion d'ions
C07H 1/08 - SéparationPurification à partir de produits naturels
The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of fermentation of metabolically engineered cells. The present invention describes new sucrose permease polypeptides, and their applications. The present invention also describes a metabolically engineered cell for the production of a glycosylated product using the novel sucrose permease polypeptides. Furthermore, the present invention provides a method for the production of a glycosylated product by a cell using the novel sucrose permease polypeptides as well as the purification of said glycosylated product from the cultivation.
The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of cultivation of genetically engineered cells. The present invention describes (i) a method of producing a saccharide comprising a lacto-N-triose or 2'-5 fucosyllactose or 3-fucosyllactose as a core trisaccharide by cultivation a genetically modified cell comprising a modified MdfA transporter and/or modified MdfA transporter homolog for the transport of said saccharide, as well as (ii) the genetically engineered cell used in the method.
This disclosure is in the technical field of cell cultivation or fermentation for the production of oligosaccharides. This disclosure discloses a method to produce a purified mixture of different oligosaccharides produced by a cell cultivation or microbial fermentation.
C12P 19/04 - Polysaccharides, c.-à-d. composés contenant plus de cinq radicaux saccharide reliés entre eux par des liaisons glucosidiques
B01D 15/36 - Adsorption sélective, p. ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction ionique, p. ex. échange d'ions, paire d'ions, suppression d'ions ou exclusion d'ions
C07H 1/08 - SéparationPurification à partir de produits naturels
48.
FUCOSYLATED SACCHARIDE FOR USE IN THE PREVENTION OR TREATMENT OF BACTERIAL DISEASE
The present invention relates to a fucosylated saccharide, or a composition comprising a fucosylated saccharide, for use in preventing and/or treating a bacterial infection in a subject, preferably streptococcosis.
The present invention relates to a fucosylated saccharide, or a composition comprising a fucosylated saccharide, for use in preventing and/or treating a parasite infection in a subject, preferably cryptosporidiosis.
The disclosure is in the technical field of synthetic biology and metabolic engineering. Described is the use of a new type of galactosyltransferases for the production of a galactosylated di- or oligosaccharide. The disclosure also describes methods for the production of a galactosylated di- or oligosaccharide as well as the purification of the di- or oligosaccharide. Furthermore, the disclosure is in the field of cultivation or fermentation of metabolically engineered cells. The disclosure provides a cell metabolically engineered for production of a galactosylated di- or oligosaccharide.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
This specification relates to a process for preparing a purified human milk oligosaccharide (“HMO”) from an HMO-containing solution (e.g., a fermentation broth) by a process comprising mixed bed ion exchange, and a product of such a process.
C07H 1/08 - SéparationPurification à partir de produits naturels
C07H 3/06 - Oligosaccharides, c.-à-d. saccharides comportant de trois à cinq radicaux saccharide liés entre eux par des liaisons glucosidiques
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A23L 33/00 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement
This disclosure is in the technical field of synthetic biology and metabolic engineering. More particularly, this disclosure is in the technical field of fermentation of metabolically engineered microorganisms. This disclosure describes engineered micro-organisms able to synthesize sialylated compounds via an intracellular biosynthesis route. These micro-organisms can dephosphorylate N-acetylglucosamine-6-phosphate to N-acetyl glucosamine and convert the N-acetylglucosamine to N-acetylmannosamine. These micro-organisms also have the ability to convert N-acetylmannosamine to N-acetyl-neuraminate. Furthermore, this disclosure provides a method for the large scale in vivo synthesis of sialylated compounds, by culturing a microorganism in a culture medium, optionally comprising an exogenous precursor such as, but not limited to lactose, lactoNbiose, N-acetyllactosamine and/or an aglycon, wherein the microorganism intracellularly dephosphorylates N-acetylglucosamine-6-phosphate to N-acetylglucosamine, converts N-acetylglucosamine to N-acetylmannosamine and convert the latter further to N-acetyl-neuraminate.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)
C12N 9/16 - Hydrolases (3.) agissant sur les liaisons esters (3.1)
C12N 9/80 - Hydrolases (3.) agissant sur les liaisons carbone-azote autres que les liaisons peptidiques (3.5) agissant sur les liaisons amides des amides aliphatiques
The present invention relates to methods for producing 2′ fucosyllactose (2′-FL), as well as newly identified fucosyltransferases, more specifically newly identified lactose binding α-1,2-fucosyltransferase polypeptides, and their applications. Furthermore, the present invention provides methods for producing 2-fucosyllactose (2′FL) using the newly identified α-1,2-fucosyltransferases.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
The disclosure is in the technical field of synthetic biology and metabolic engineering. More particularly, the disclosure is in the technical field of metabolically engineered cells and use of the cells in a cultivation or fermentation. The disclosure describes a metabolically engineered cell and a method by cultivation or fermentation with the cell for production of a sialylated di- and/or oligosaccharide. The metabolically engineered cell comprises a pathway for production of the sialylated di- and/or oligosaccharide and is modified for expression and/or overexpression of multiple coding DNA sequences encoding one or more isoproteins that catalyze the same chemical reaction. Furthermore, the disclosure provides for purification of the sialylated di- and/or oligosaccharide from the cultivation.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
55.
PRODUCTION OF GLCNAC CONTAINING BIOPRODUCTS IN A CELL
The disclosure is in the technical field of synthetic biology and metabolic engineering. More particularly, the disclosure is in the technical field of cultivation or fermentation of metabolically engineered cells. The disclosure describes a method for the production of a di- or oligosaccharide with an N-acetylglucosamine at the reducing end by a cell as well as the purification of the di- or oligosaccharide from the cultivation. Furthermore, the disclosure provides a cell metabolically engineered for production of a di- or oligosaccharide with an N-acetylglucosamine at the reducing end.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
The present invention is in the technical field of synthetic biology, metabolic engineering and cell cultivation. The present invention relates to newly identified sialyltransferases having alpha-2, 3- sialyltransferase activity on the galactose residue of lactose. The invention also describes methods for the production of a 3'sialylated oligosaccharide using any one of said newly identified sialyltransferases as well as the purification of said 3'sialylated oligosaccharide. The present invention also provides a cell for production of said 3'sialylated oligosaccharide and the use of said cell in a cultivation or incubation.
The present invention is in the technical field of synthetic biology, metabolic engineering and cell cultivation. The present invention relates to newly identified alpha-2, 6-sialyltransferases having alpha- 2,6-sialyltransferase activity on the terminal galactose residue of lacto-N-neotetraose (Gal-β1,4-GlcNAc-β1,3-Gal-β1,4-Glc). The invention also describes methods for the production of a sialylated oligosaccharide using any one of said newly identified alpha-2, 6-sialyltransferases as well as the purification of said sialylated oligosaccharide. The present invention also provides a cell for production of said sialylated oligosaccharide and the use of said cell in a cultivation or incubation.
C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
C12P 19/26 - Préparation d'hydrates de carbone contenant de l'azote
This disclosure is in the technical field of synthetic biology and metabolic engineering. More particularly, this disclosure is in the technical field of cultivation or fermentation of metabolically engineered cells. This disclosure provides a method for the production of a mixture of at least two different oligosaccharides by a cell as well as the purification of at least one of the oligosaccharides from the cultivation. In addition, this disclosure provides a method for the production of a mixture of at least two different oligosaccharides by a metabolically engineered cell as well as the purification of at least one of the oligosaccharides from the cultivation.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
The disclosure is in the technical field of synthetic biology and metabolic engineering. More particularly, the disclosure is in the technical field of cultivation or fermentation of metabolically engineered cells. The disclosure describes a cell metabolically engineered for production of an alpha-1,3 glycosylated form of fucose-alpha1,2-galactose-R (Fuc-a1,2-Gal-R). Furthermore, the disclosure provides a method for the production of an alpha-1,3 glycosylated form of Fuc-a1,2-Gal-R by a cell as well as the purification of the alpha-1,3 glycosylated form Fuc-a1,2-Gal-R from the cultivation.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
The disclosure is in the technical field of synthetic biology and metabolic engineering. More particularly, the disclosure is in the technical field of cultivation or fermentation of metabolically engineered cells. The disclosure describes a cell metabolically engineered for production of a mixture of at least four different neutral non-fucosylated oligosaccharides. Furthermore, the disclosure provides a method for the production of a mixture of at least four different neutral non-fucosylated oligosaccharides by a cell as well as the purification of at least one of the oligosaccharides from the cultivation.
C12N 1/00 - Micro-organismes, p. ex. protozoairesCompositions les contenantProcédés de culture ou de conservation de micro-organismes, ou de compositions les contenantProcédés de préparation ou d'isolement d'une composition contenant un micro-organismeLeurs milieux de culture
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
C12P 7/58 - Acides aldoniques, céto-aldoniques ou sacchariques
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
C12P 19/26 - Préparation d'hydrates de carbone contenant de l'azote
61.
Production of Sialylated Oligosaccharide in Host Cells
The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of fermentation of metabolically engineered host cells. The present invention describes a method of making sialylated oligosaccharide by fermentation with a genetically modified cell, as well as to the genetically modified cell used in the method. The genetically modified cell comprises at least one nucleic acid sequence coding for an enzyme involved in sialylated oligosaccharide synthesis and at least one nucleic acid expressing a membrane protein.
C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
The present invention is in the technical field of synthetic biology, metabolic engineering and cell cultivation. The present invention describes methods for the production of a fucosylated compound comprising Gal-β1,3-[Fuc-α1,4]-GlcNAc using a fucosyltransferase as well as the purification of said fucosylated compound, said fucosyltransferase having alpha-1,4-fucosyltransferase activity on the N-acetylglucosamine (GIcNAc) residue of Gal-β1,3-GlcNAc (lacto-N-biose, LNB) and/or Gal-β1,3-GlcNAc of a saccharide substrate comprising Gal-β1,3-GlcNAc. The present invention also provides a cell for production of a fucosylated compound comprising Gal-β1,3-[Fuc-α1,4]-GlcNAc.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
The present invention is in the technical field of synthetic biology, metabolic engineering and cell cultivation. The present invention describes methods for the production of a fucosylated compound using a fucosyltransferase as well as the purification of said fucosylated compound, said fucosyltransferase having alpha-1,3-fucosyltransferase activity on the N-acetylglucosamine (GlcNAc) and/or the glucose (Glc) residue of Gal-β1,m-GlcNAc-β1,n-Gal-β1,4-Glc of a saccharide substrate comprising Gal-β1,m-GlcNAc- β1,n-Gal-β1,4-Glc wherein said m is 3 or 4 and said n is 3 or 6. The present invention also provides a cell for production of a fucosylated compound. Next, the present invention describes methods for the production of 3-fucosyllactose (3-FL) using a fucosyltransferase having alpha-1,3-fucosyltransferase activity on the Glc residue of lactose, as well as the purification of said 3-FL. The present invention also provides a cell for production of 3-FL.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
C07H 1/08 - SéparationPurification à partir de produits naturels
The present invention lies in the technical field of drying an oligosaccharide. The present application discloses a method for drying an oligosaccharide or mixture of at least two oligosaccharides by using agitated thin film drying (ATFD), wherein said oligosaccharide or each oligosaccharide of said mixture has a degree of polymerization which is lower than 16.
The present invention relates to newly identified alpha-2,6-sialyltransferases. The invention also provides for production of sialylated di- and/or oligosaccharides and relates to the use of the sialyltransferases in such methods and cells. The present invention is also in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of metabolically engineered cells and use of said cells in a cultivation or incubation. The present invention describes a metabolically engineered cell and a method by cultivation or incubation with said cell for production of 6'sialylated disaccharide and/or 6'sialylated oligosaccharide. Furthermore, the present invention provides for purification of said 6'sialylated disaccharide and/or 6'sialylated oligosaccharide from the cultivation or incubation.
C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
66.
KDO-FREE PRODUCTION HOSTS FOR OLIGOSACCHARIDE SYNTHESIS
This disclosure relates to the technical field of synthetic biology and metabolic engineering. More particularly, this disclosure relates to the technical field of fermentation of metabolically engineered microorganisms. This disclosure describes engineered micro-organisms that produce oligosaccharides that are free of KDO-lactose impurities and/or KDO-oligosaccharide impurities.
C12P 19/04 - Polysaccharides, c.-à-d. composés contenant plus de cinq radicaux saccharide reliés entre eux par des liaisons glucosidiques
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
C12P 19/26 - Préparation d'hydrates de carbone contenant de l'azote
The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of metabolically engineered cells and use of said cells in a cultivation, preferably a fermentation. The present invention describes a cell and a method for production of a compound. The cell expresses an alpha-1,2-fucosyltransferase that has galactoside alpha-1,2-fucosyltransferase activity on the galactose residue of Gal-b1,3-GlcNAc (LNB, lacto-N-biose). Furthermore, the present invention provides for purification of said compound from the cultivation.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
The present disclosure is in the technical field of synthetic biology and metabolic engineering. The disclosure provides engineered viable bacteria. In particular, the disclosure provides viable bacteria with reduced cell wall biosynthesis additionally modified for production of glycosylated product. The disclosure further provides methods of generating viable bacteria and uses thereof. Furthermore, the disclosure in the technical field of fermentation of metabolically engineered microorganisms producing glycosylated product.
The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of metabolically engineered cells and use of said cell in a cultivation, preferably a fermentation. The present invention describes a cell for the production of a compound. The cell comprises a pathway for the production of the compound, which can be a disaccharide, oligosaccharide and/or a Neu(n)Ac-containing bioproduct, wherein (n) is 4, 5, 7, 8 or 9 or a combination thereof. The cell is metabolically engineered for enhanced synthesis of acetyl-Coenzyme A. The invention also resides in a method of producing such compound by cultivation, preferably a fermentation, with such a cell.
The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of metabolically engineered cells of microorganisms and the use of said cells in a fermentation. The present invention describes a metabolically engineered cell of a microorganism and a method by fermentation with said cell for production of a sialylated di- and/or oligosaccharide. The metabolically engineered cell comprises a pathway for production of said sialylated di- and/or oligosaccharide, synthesizes sialic acid, expresses at least one sialyltransferase, preferably is modified in the expression or activity of at least one sialyltransferase, is modified to have a fully or partially knocked out or rendered less functional sialic acid catabolic pathway and is modified for overexpression of an endogenous sialic acid transporter and/or expression, preferably overexpression, of an exogenous, homologous and/or heterologous sialic acid transporter. Furthermore, the present invention provides for purification of said sialylated di- and/or oligosaccharide from the cultivation, preferably fermentation.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
C12P 19/26 - Préparation d'hydrates de carbone contenant de l'azote
The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of metabolically engineered cells and use of said cells in a cultivation, preferably fermentation. The present invention describes a metabolically engineered cell and a method by culutivation, preferably fermentation, with said cell for production of a bioproduct. More specifically, the present invention describes a metabolically engineered cell and a method by cultivation, preferably fermentation, with said cell for production of an N-acetylneuraminic acid (Neu(n)Ac)-containing compound, wherein (n) is 4, 5, 7, 8 or 9 or a combination thereof. The metabolically engineered cell comprises a pathway for production of said Neu(n)Ac-containing compound and is modified in the expression or activity of at least one NeuNAc synthase according to the present invention. Furthermore, the present invention provides for purification of said Neu(n)Ac-containing compound from the cultivation.
The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention relates to a method to determine the expression stability of a heterologous gene at a chromosomal location in a cell undergoing burden and to produce mutated cells or organisms transformed with a heterologous gene at a chromosomal location, wherein the expression of said heterologous gene is not influenced by a burden or wherein the expression of said heterologous gene is reduced by a burden. The present invention describes methods to locate interesting chromosomal knock-in locations in a cell. Such engineered cells and organisms are applied for the production of bioproducts, such as but not limited to carbohydrates, lipids, proteins, organic acids, amino acids, alcohols, antibiotics and peptides. Preferably, the invention is applied in the technical field of fermentation of metabolically engineered microorganisms.
This disclosure is in the technical field of synthetic biology and metabolic engineering. More particularly, this disclosure is in the technical field of fermentation of metabolically engineered host cells. The disclosure describes a method of producing fucosyllactose by fermentation with a genetically modified cell, as well as to the genetically modified cell used in the method. The genetically modified cell comprises at least one nucleic acid sequence coding for an enzyme involved in fucosyllactose synthesis; more specifically, the cell comprises a nucleic acid sequence coding for a fucosyltransferase, thereby synthesizing fucosyllactose and at least one nucleic acid expressing a membrane protein, more specifically, a nucleic acid sequence expressing a membrane protein enabling fucosyllactose transport.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
The present invention concerns a method of producing an oligosaccharide comprising a lacto-N-triose (LN3; GlcNAc-beta-1,3-Gal-beta-l,4-Glc) as a core trisaccharide by cultivation with a genetically modified cell, as well as the genetically modified cell used in the method. The genetically modified cell comprises at least one nucleic acid sequence coding for a galactoside beta-1, 3-N-acetylglucosaminyltransferase and a glycosyltransferase involved in the synthesis of an oligosaccharide comprising LN3 as a core trisaccharide and at least one nucleic acid sequence expressing a membrane protein. Furthermore, the present invention provides for a purification of said oligosaccharide comprising LN3 as a core trisaccharide from the cultivation.
C12P 19/26 - Préparation d'hydrates de carbone contenant de l'azote
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
C07K 14/195 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries
The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of cultivation of metabolically engineered cells. The present invention describes a method for the production of a glycosylated product derived from UDP- GIcNAc and comprising a di- or oligosaccharide that is composed of at least two different monosaccharide subunits by a cell as well as the separation of said glycosylated product from the cultivation. Furthermore, the present invention provides a metabolically engineered cell for production of a glycosylated product derived from UDP-GIcNAc and comprising a di- or oligosaccharide that is composed of at least two different monosaccharide subunits. The present invention also provides a cell excreting a di- or oligosaccharide out of the cell.
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of fermentation of metabolically engineered yeast or fungal cells. The present invention describes a method for the extracellular production of a di- or oligosaccharide that is derived from UDP-GlcNAc by a yeast or fungal cell as well as the separation of said di- or oligosaccharide from the cultivation. Furthermore, the present invention provides a metabolically engineered yeast or fungal cell for extracellular production of a di- or oligosaccharide that is derived from UDP-GlcNAc and that is synthesized in the cytosol.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
C12N 15/81 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour champignons pour levures
The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of fermentation of metabolically engineered cells. The present invention describes new sucrose permease polypeptides, and their applications. The present invention also describes a metabolically engineered cell for the production of a glycosylated product using the novel sucrose permease polypeptides. Furthermore, the present invention provides a method for the production of a glycosylated product by a cell using the novel sucrose permease polypeptides as well as the purification of said glycosylated product from the cultivation.
This specification relates to a process for preparing a purified human milk oligosaccharide ("HMO") from an HMO-containing solution (e.g., a fermentation broth) by a process comprising mixed bed ion exchange, and a product of such a process.
C07H 3/06 - Oligosaccharides, c.-à-d. saccharides comportant de trois à cinq radicaux saccharide liés entre eux par des liaisons glucosidiques
A23C 9/146 - Préparations à base de laitLait en poudre ou préparations à base de lait en poudre dans lesquelles la composition chimique du lait est modifiée par des traitements non chimiques par échange d'ions
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A23L 33/21 - Adjonction de substances essentiellement non digestibles, p. ex. de fibres diététiques
A23L 33/00 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement
79.
PROCESS FOR PURIFYING A HUMAN MILK OLIGOSACCHARIDE AND RELATED COMPOSITIONS
This specification relates to a process for preparing a purified human milk oligosaccharide ("HMO") from an HMO-containing solution (e.g., a fermentation broth) by a process comprising anion ion exchange, cation ion exchange, and mixed bed ion exchange; and a product of such a process.
C07H 3/06 - Oligosaccharides, c.-à-d. saccharides comportant de trois à cinq radicaux saccharide liés entre eux par des liaisons glucosidiques
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A23L 33/21 - Adjonction de substances essentiellement non digestibles, p. ex. de fibres diététiques
A23L 33/00 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement
A23C 9/146 - Préparations à base de laitLait en poudre ou préparations à base de lait en poudre dans lesquelles la composition chimique du lait est modifiée par des traitements non chimiques par échange d'ions
80.
PRODUCTION OF AN OLIGOSACCHARIDE MIXTURE BY A CELL
The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of cultivation or fermentation of metabolically engineered cells. The present invention describes a cell metabolically engineered for production of a mixture of at least three different oligosaccharides. Furthermore, the present invention provides a method for the production of a mixture of at least three different oligosaccharides by a cell as well as the purification of at least one of said oligosaccharides from the cultivation.
C12P 19/04 - Polysaccharides, c.-à-d. composés contenant plus de cinq radicaux saccharide reliés entre eux par des liaisons glucosidiques
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
81.
PRODUCTION OF A MIXTURE OF NEUTRAL FUCOSYLATED OLIGOSACCHARIDES BY A CELL
Production of a mixture of neutral fucosylated oligosaccharides by a cell The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of cultivation or fermentation of metabolically engineered cells. The present invention describes a cell metabolically engineered for production of a neutral mixture of at least four different neutral fucosylated oligosaccharides. Furthermore, the present invention provides a method for the production of a neutral mixture of at least four different neutral fucosylated oligosaccharides by a cell as well as the purification of at least one of said neutral oligosaccharides from the cultivation.
C12P 19/04 - Polysaccharides, c.-à-d. composés contenant plus de cinq radicaux saccharide reliés entre eux par des liaisons glucosidiques
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
82.
PRODUCTION OF A SIALYLATED OLIGOSACCHARIDE MIXTURE BY A CELL
The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of cultivation or fermentation of metabolically engineered cells. The present invention describes a cell metabolically engineered for production of a mixture of at least three different sialylated oligosaccharides. Furthermore, the present invention provides a method for the production of a mixture of at least three different sialylated oligosaccharides
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
The present invention is in the technical field of synthetic biology and metabolic engineering. The present invention describes methods for the production of 2',3-difucosyllactose as well as the purification of said 2',3-difucosyllactose from the mixture. The present invention describes methods for the production of a mixture of 2',3-difucosyllactose, 2'-fucosyllactose and/or 3-fucosyllactose as well as the purification of any one of said 2'-fucosyllactose, 3-fucosyllactose and 2',3-difucosyllactose from the mixture. The present invention also describes a method for the production of 2',3-difucosyllactose with a purity of at least 80% based on the total amount of 2'-fucosyllactose, 3-fucosyllactose and 2',3-difucosyllactose produced. Furthermore, the present invention is in the technical field of cultivation or fermentation of metabolically engineered cells. The present invention describes a cell metabolically engineered for production of 2',3- difucosyllactose or a mixture of 2',3-difucosyllactose, 2'-fucosyllactose and/or 3-fucosyllactose.
C12P 19/04 - Polysaccharides, c.-à-d. composés contenant plus de cinq radicaux saccharide reliés entre eux par des liaisons glucosidiques
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
84.
PRODUCTION OF GLCNAC CONTAINING BIOPRODUCTS IN A CELL
The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of cultivation or fermentation of metabolically engineered cells. The present invention describes a method for the production of a di- or oligosaccharide with an N-acetylglucosamine at the reducing end by a cell N-acetylglucosamine and by expressing N-acetylglucosamine b-1,3-galactosyltransferase like WbgO or by expressing N-acetylglucosamine b-1,4-galactosyltransferase like LgtB, as well as the purification of said di- or oligosaccharide like lacto- N-biose, LNB or N-acetyllactosamine, LacNAc from the cultivation. Furthermore, the present invention provides a cell metabolically engineered for production of a di- or oligosaccharide with an N- acetylglucosamine at the reducing end.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
The present invention is in the technical field of synthetic biology and metabolic engineering. The present invention describes the use of a new type of galactosyltransferases for the production of a galactosylated di- or oligosaccharide. The present invention also describes methods for the production of a galactosylated di- or oligosaccharide as well as the purification of said di- or oligosaccharide. Furthermore, the present invention is in the field of cultivation or fermentation of metabolically engineered cells. The present invention provides a cell metabolically engineered for production of a galactosylated di- or oligosaccharide.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
Production of alpha-1,3 glycosylated form of Fuc-a1,2-Gal-R The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of cultivation or fermentation of metabolically engineered cells. The present invention describes a cell metabolically engineered for production of an alpha-1,3 glycosylated form of fucose-alpha1,2-galactose-R (Fuc-a1,2-Gal-R). Furthermore, the present invention provides a method for the production of an alpha-1,3 glycosylated form of Fuc-a1,2-Gal-R by a cell as well as the purification of said alpha-1,3 glycosylated form Fuc-a1,2-Gal-R from the cultivation.
C12P 19/04 - Polysaccharides, c.-à-d. composés contenant plus de cinq radicaux saccharide reliés entre eux par des liaisons glucosidiques
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
87.
CELLULAR PRODUCTION OF DI- AND/OR OLIGOSACCHARIDES
The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of metabolically engineered cells and use of said cells in a cultivation or fermentation. The present invention describes a cell and a method for production of a di- and/or oligosaccharide. The cell comprises a pathway for production of said di- and/or oligosaccharide and is genetically modified for expression and/or overexpression of at least one set of multiple coding DNA sequences wherein the multiple coding DNA sequences within one set differ in nucleotide sequence and each encode a polypeptide, wherein said polypeptides have the same function and/or activity of interest. Furthermore, the present invention provides for purification of said di- and/or oligosaccharide from the cultivation.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
C12P 19/26 - Préparation d'hydrates de carbone contenant de l'azote
88.
PRODUCTION OF AN OLIGOSACCHARIDE MIXTURE BY A CELL
The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of cultivation or fermentation of metabolically engineered cells. The present invention describes a cell metabolically engineered for production of a mixture of at least three different oligosaccharides. Furthermore, the present invention provides a method for the production of a mixture of at least three different oligosaccharides by a cell as well as the purification of at least one of said oligosaccharides from the cultivation.
C12P 19/04 - Polysaccharides, c.-à-d. composés contenant plus de cinq radicaux saccharide reliés entre eux par des liaisons glucosidiques
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
89.
PRODUCTION OF A MIXTURE OF MAMMALIAN MILK OLIGOSACCHARIDES BY A CELL
The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of cultivation or fermentation of metabolically engineered cells. The present invention describes a cell metabolically engineered for production of a mixture of at least three different mammalian milk oligosaccharides. Furthermore, the present invention provides a method for the production of a mixture of at least three different mammalian milk oligosaccharides by a cell as well as the purification of at least one of said mammalian milk oligosaccharides from the cultivation.
C12P 19/04 - Polysaccharides, c.-à-d. composés contenant plus de cinq radicaux saccharide reliés entre eux par des liaisons glucosidiques
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
90.
PRODUCTION OF A MIXTURE OF NEUTRAL NON-FUCOSYLATED OLIGOSACCHARIDES BY A CELL
023-PCT 126 Abstract Production of a mixture of neutral non-fucosylated oligosaccharides by a cell The present invention is in the technical field of synthetic biology and metabolic engineering. More 5 particularly, the present invention is in the technical field of cultivation or fermentation of metabolically engineered cells. The present invention describes a cell metabolically engineered for production of a mixture of at least four different neutral non-fucosylated oligosaccharides. Furthermore, the present invention provides a method for the production of a mixture of at least four different neutral non- fucosylated oligosaccharides by a cell as well as the purification of at least one of said oligosaccharides 10 from the cultivation. 15
C12P 19/04 - Polysaccharides, c.-à-d. composés contenant plus de cinq radicaux saccharide reliés entre eux par des liaisons glucosidiques
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of cultivation or fermentation of metabolically engineered cells. The present invention provides a method for the production of a mixture of at least two different oligosaccharides by a cell as well as the purification of at least one of said oligosaccharides from the cultivation. In addition, the present invention provides a method for the production of a mixture of at least two different oligosaccharides by a metabolically engineered cell as well as the purification of at least one of said oligosaccharides from the cultivation.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
92.
METHOD TO PRODUCE A PURIFIED MIXTURE OF DIFFERENT OLIGOSACCHARIDES PRODUCED BY CELL CULTIVATION OR MICROBIAL FERMENTATION
The present invention is in the technical field of cell cultivation or fermentation for the production of oligosaccharides. The present application discloses a method to produce a purified mixture of different oligosaccharides produced by a cell cultivation or microbial fermentation.
B01D 15/36 - Adsorption sélective, p. ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction ionique, p. ex. échange d'ions, paire d'ions, suppression d'ions ou exclusion d'ions
93.
PROCESS FOR PURIFICATION OF AN OLIGOSACCHARIDE SOLUTION PRODUCED BY CELL CULTIVATION OR MICROBIAL FERMENTATION
The present invention is in the technical field of cell cultivation or fermentation for the production of oligosaccharides. The present application discloses a process for purification of an oligosaccharide solution produced by microbial fermentation.
B01D 15/36 - Adsorption sélective, p. ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction ionique, p. ex. échange d'ions, paire d'ions, suppression d'ions ou exclusion d'ions
94.
CELLULAR PRODUCTION OF SIALYLATED DI- AND/OR OLIGOSACCHARIDES
The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of metabolically engineered cells and use of said cells in a cultivation or fermentation. The present invention describes a metabolically engineered cell and a method by cultivation or fermentation with said cell for production of a sialylated di- and/or oligosaccharide. The metabolically engineered cell comprises a pathway for production of said sialylated di- and/or oligosaccharide and is modified for expression and/or overexpression of multiple coding DNA sequences encoding one or more isoproteins that catalyse the same chemical reaction. Furthermore, the present invention provides for purification of said sialylated di- and/or oligosaccharide from the cultivation.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
C12P 19/26 - Préparation d'hydrates de carbone contenant de l'azote
95.
PRODUCTION OF 3-FUCOSYLLACTOSE AND LACTOSE CONVERTING ALPHA-1,3-FUCOSYLTRANSFERASE ENZYMES
Methods for producing 3-fucosyllactose (3-FL) as well as novel fucosyltransferases, more specifically novel lactose binding alpha-1,3-fucosyltransferase polypeptides, and their applications. Furthermore, methods are provided for producing 3-fucosyllactose (3-FL) using the novel lactose binding alpha-1,3-fucosyltransferases.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
29 - Viande, produits laitiers et aliments préparés ou conservés
30 - Aliments de base, thé, café, pâtisseries et confiseries
31 - Produits agricoles; animaux vivants
32 - Bières; boissons non alcoolisées
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemicals, namely specialty carbohydrates, complex sugars,
oligosaccharides and rare monosaccharides, all produced by
innovative bio-technological processes and for use in the
food, feed, cosmetic, nutraceutical and pharmaceutical
industries or for use in science as well as in agriculture
(except fungicides, herbicides, insecticides and
parasiticides); specialty carbohydrate and/or human milk
oligosaccharide (HMO) preparations for use in the industry
and for use as raw material in the manufacture of other
goods, all not for medical purposes; human milk
oligosaccharide (HMO) additives for use in the manufacture
of pharmaceuticals, nutraceuticals, infant formula,
foodstuffs and of animal foods; human milk oligosaccharide
compounds, chemical and biological derivatives of human milk
oligosaccharide compounds and chemical and biological
precursors of human milk oligosaccharide compounds, all for
the food industry; human milk oligosaccharide compounds,
chemical and biological derivatives of human milk
oligosaccharide compounds and chemical and biological
precursors of human milk oligosaccharide compounds, all for
scientific use and other than for medical or veterinary use;
human milk oligosaccharide compounds, chemical and
biological derivatives of human milk oligosaccharide
compounds and chemical and biological precursors of human
milk oligosaccharide compounds, all for industrial use;
human milk oligosaccharide compounds, chemical and
biological derivatives of human milk oligosaccharide
compounds and chemical and biological precursors of human
milk oligosaccharide compounds, all for in the manufacture
of pharmaceuticals, nutraceuticals, infant formula,
foodstuffs and of animal foods; chemicals for industrial
use, for use as chemical ingredients for use in the
manufacture of dietary supplements and infant formula. Cosmetics on the base of specialty carbohydrates. Pharmaceutical and veterinary preparations; dietetic
substances adapted for medical use; formulated milk, food
and food substances, all for babies; infant formula,
including growing up formula; beverages for babies; dietetic
drinks for babies; dietetic drinks for infants, children and
toddlers, for medical use; food and food substances for
children and invalids, all adapted for medical use;
nutritional and dietary supplements adapted for medical use;
food for special medical purposes (FSMP); pharmaceuticals or
medical products for human use; sanitary preparations for
medical purposes; medical preparations; medical
dermatological preparations; biotechnological products for
medical use, for human beings; medical preparations and
medical products in tablet form; tincture for medical
purposes; ointments for pharmaceutical purposes; lotions for
pharmaceutical purposes; capsules for pharmaceutical
purposes; pharmaceutical preparations for skin care;
pharmaceutical and veterinary specialty carbohydrate based
preparations; nutritional supplements; plasters; dressings
for burns and wounds; surgical dressings; material for
stopping teeth; dental wax; disinfectants; preparations for
destroying vermin; fungicides; herbicides; nutritional
drinks and other food supplements; nutritionally enhanced
fruit juices and fruit juice-based products, all for medical
purposes; nutritionally enhanced milk for medical purposes;
nutritionally enhanced mineral and aerated waters, for
medical purposes; nutritionally enhanced lotions, salves and
balms, all for medical use; nutritionally fortified water
for medical use; nutritional powders and bars (food
supplements); food supplements in the form of nutritional
bars and in powder form, for use in making nutritional
shakes; nutritional and dietary supplements, in powder,
capsule, tablets, gels, partially and fully reconstituted
liquids and bar form; meal replacements in bar, powder and
liquid form (food supplements); dietetic products for
medical use; food supplements prepared for human consumption
for medical use; nutritional beverages in powder form or in
liquid form (food supplements); fortifying food supplements;
restorative food supplements; mineral food supplements;
colostrum food supplements; dietary supplemental drinks
(food supplements); mineral, vitamin or nutritionally
enhanced water, for medical use; nutritionally fortified
beverages for medical use; dietetic foods and beverages and
strengthening dietetic foods and substances, all adapted for
medical use, including for clinical use; food additives for
baby and animals; veterinary products for animal health;
medicated oral health care products; dietary supplements for
humans and animals; dietetic food and beverages adapted for
biomedical or veterinary use; medicated additives and
supplements for animal nutrition; medicated biochemicals for
animal feed and nutrition; dietetic food and substances,
namely, specialty carbohydrate and/or human milk
oligosaccharide adapted for medical or veterinary use;
medicated food additives in the nature of dietary
supplements containing human milk oligosaccharide for humans
and for animals; medicated preparations for use as additives
for food for human or animal consumption, namely human milk
oligosaccharide for medical or veterinary purposes; vitamin
supplements for dietary use; food supplements for dietetic
use; dietary supplements for medical use; medicated
supplements for foodstuffs for humans, including for infants
and for animals; dietary supplemental drinks for medical
use; dietary supplements for infants; human milk
oligosaccharide dietary supplements; human milk
oligosaccharide compounds for medical purposes; human milk
oligosaccharide additives being dietary and nutritional
supplements for use as supplements in connection with
pharmaceuticals, nutraceuticals and with infant formula;
human milk oligosaccharide additives for use as a dietary or
nutritional supplement; human milk oligosaccharide compounds
and chemical and biological derivatives of human milk
oligosaccharide compounds, all for medical use. Dairy products; milk; milk powder; flavoured jellified milk
and whipped milk products; dairy based desserts; yoghurts;
drinking yoghurts; dairy based mousses and creams; cream
desserts; dairy fresh cream; butter, cheese spreads, cheese,
ripened cheese, mould-ripened cheese, fresh unripened cheese
and cheese in brine; soft white cheese; strained soft white
cheese; plain or aromatised fresh cheese in pasty or liquid
form; beverages mainly consisting of milk or dairy products;
milk beverages containing fruits; plain or flavoured
fermented dairy products; milk beverages containing lactic
ferments, not for medical use. Specialty carbohydrate and/or human milk oligosaccharide
preparations for culinary purposes; specialty carbohydrate
and/or human milk oligosaccharide compounds and chemical and
biological derivatives of human milk oligosaccharide
compounds for culinary purposes; processed cereals for human
consumption; cereal preparations, ready-to-eat cereals,
breakfast cereals and cereals bars for human consumption;
coffee; tea; confectionary. Animal food; animal feed and feedstuffs. Beers; mineral and aerated waters and other non-alcoholic
drinks; fruit drinks and fruit juices; syrups and other
preparations for making beverages; soft drinks containing
small quantities of dairy products; non-alcoholic beverages
containing small quantities of lactic ferments;
non-alcoholic beverages containing fruits; non-alcoholic
fruit nectars; natural fruit juices without additives; apple
juices, grape juices, orange juices, pineapple juices,
grapefruit juices, cherry juices, prune juices, peach
juices, apricot juices, apple and black currant juices,
apple and cherry juices, mixed fruit juices; vegetable
juices, tomato juices, carrot juices and apple and carrot
juices, all being beverages; light non-alcoholic beverage;
nutritionally fortified beverages, including on the base of
fruit drinks or fruit juices; nutritionally fortified waters
and soft drinks; sports drinks; drinking water with
vitamins; flavoured drinking water nutritionally enhanced
with vitamins and minerals; sports drinks containing
electrolytes, vitamins and minerals; performance enhancing
nutritionally fortified beverages, not for medical use. Scientific and technological research and design in the
field of biotechnology relating to carbohydrate and
specialty carbohydrate production; industrial analysis and
research services in the field of biotechnology relating to
carbohydrate and specialty carbohydrate production; design
and development of upstream and downstream processing in the
production of carbohydrates and specialty carbohydrates;
scientific, biotechnological and technological evaluation
and development in the field of carbohydrate and specialty
carbohydrate production; research and development of new
specialty carbohydrate products; scientific research related
to biomedical issues and to issues on clinical nutrition,
prebiotics, cosmetics, crop protection, plant disease and on
fertilization management; industrial and scientific research
in the field of biotechnology and specialty carbohydrates.
97.
KDO-FREE PRODUCTION HOSTS FOR OLIGOSACCHARIDE SYNTHESIS
The present invention relates to the technical field of synthetic biology and metabolic engineering. More particularly, the present invention relates to the technical field of fermentation of metabolically engineered microorganisms. The present invention describes engineered micro-organisms which produce oligosaccharides which are free of KDO-lactose impurities and/or KDO-oligosaccharide impurities.
The present invention is in the technical field of synthetic biology and metabolic engineering. The present invention provides engineered viable bacteria. In particular, the present invention provides viable bacteria with reduced cell wall biosynthesis additionally modified for production of glycosylated product. The present invention further provides methods of generating viable bacteria and uses thereof. Furthermore, the present invention is in the technical field of fermentation of metabolically engineered microorganisms producing glycosylated product.
C12P 19/00 - Préparation de composés contenant des radicaux saccharide
C12P 1/00 - Préparation de composés ou de compositions, non prévue dans les groupes , utilisant des micro-organismes ou des enzymesProcédés généraux de préparation de composés ou de compositions utilisant des micro-organismes ou des enzymes
The present invention relates to the technical field of synthetic biology and metabolic engineering. More particularly, the present invention relates to the technical field of fermentation of metabolically engineered microorganisms. The present invention describes engineered micro-organisms which produce oligosaccharides which are free of KDO-lactose impurities and/or KDO-oligosaccharide impurities.
The present invention is in the technical field of synthetic biology and metabolic engineering. The present invention provides engineered viable bacteria. In particular, the present invention provides viable bacteria with mutated outer membrane biosynthetic pathway leading to disruption of said pathway, preferably substantially lacking lipopolysaccharide (LPS, endotoxin) within the outer membrane. The present invention further provides methods of generating viable bacteria and uses thereof. The present invention also provides compositions and methods for inducing immune responses and for researching and developing therapeutic agents. Furthermore, the present invention is in the technical field of fermentation of metabolically engineered microorganisms producing bioproduct or metabolite.
C12N 9/80 - Hydrolases (3.) agissant sur les liaisons carbone-azote autres que les liaisons peptidiques (3.5) agissant sur les liaisons amides des amides aliphatiques
